Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23513312 | 0.78 | KDM4E (0.33) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL9092201 | 0.73 | MAPT (0.32) | MAPT | |
| SCHEMBL9673887 | 0.72 | MAPT (0.38) | MAPTKDM4ELMNACYP2C19TSHR | |
| SCHEMBL27322268 | 0.70 | MAPT (0.35) | MAPTKDM4ELMNACYP2C19 | |
| SCHEMBL27322223 | 0.70 | MAPT (0.35) | MAPTKDM4ELMNACYP2C19 | |
| SCHEMBL11738006 | 0.70 | MAPT (0.35) | MAPTALDH1A1KDM4ELMNACYP2C19 | |
| SCHEMBL22901958 | 0.70 | KDM4E (0.33) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL22902078 | 0.70 | KDM4E (0.33) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL24518173 | 0.70 | TSHR (0.32) | MAPTTSHRHPGD | |
| SCHEMBL16097822 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076383-A1 | SULFONANILIDE AND BENZYLSULFONYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Lysoway Therapeutics, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2005063763-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-0824523-A1 | NITRIC OXIDE SYNTHASE INHIBITORS DERIVED FROM CYCLIC AMIDINES | G.D. Searle & Co. (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035677-A1 | NITRIC OXIDE SYNTHASE INHIBITORS DERIVED FROM CYCLIC AMIDINES | G.D. SEARLE & CO. (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | MAPT 671/4885ALDH1A1 467/4885KDM4E 3223/4885 |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | MAPT 671/4885ALDH1A1 467/4885KDM4E 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.